Biotron Limited (BIT.XA)
Cboe AU · AUD
A$0.003 (+0.00%) as of
Key statistics
- EPS (TTM)
- -0.0040
- 52-week range
- 0.0010 – 0.0045
- Beta
- -0.64
- Revenue (TTM)
- 525.87k
- Profit margin
- -288.72%
- Volume
- 2.00M
About Biotron Limited
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops preclinical drugs for viral diseases, such as dengue, zika, and influenza virus. The company was incorporated in 1999 and is based in Sydney, Australia.
- Headquarters
- Sydney, NSW, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.